ERBB2 and neoplasm: By subtype, 14.2% (65 of 459) of all the women with HR-positive/HER2-negative tumours received chemotherapy, compared to 43.4% (33 of 76) of all the women with triple-negative tumours and 65.7% (71 of 108) of all the women with HER2-positive tumours.